Pain Management

Axsome Therapeutics expects the therapy to be commercially available in the United States in approximately 4 months.

The decision makes the selective NaV1.8 pain signal inhibitor the first new class of medicine to treat acute pain in over 20 years.

Researchers analyzed liveborn infant data from January 2020 to June 2024 to determine prevalence, cause, and treatment strategies for pain among preterm infants.

A supratherapeutic dose of 1000 ug cebranopadol was significantly less likeable compared to 40 mg oxycodone when crushed and taken intranasally.

Researchers conducted a literature review of patients’ clinical experiences with using secukinumab to treat psoriatic arthritis.

Cebranopadol is a first-in-class investigational therapy that targets the nociceptin/orphanin FQ receptor and the µ-opioid receptor.

Older patients were more likely to receive opioid-sedative coprescriptions to treat low back pain.

A combination of ibuprofen and acetaminophen was found to be superior to hydrocodone and acetaminophen in managing pain after impacted mandibular third-molar extraction surgery.

XG005 from Xgene Pharmaceutical is a novel, non-opioid chemical entity that targets anti-nociceptive and anti-neuropathic pain pathways.

Check out this list of our top 5 most read nonopioid pain management stories from the year 2024.

Check out this list of our top 5 most read pain management stories from the year 2024.

A study found that patients with medication-overuse headache and neck pain experience earlier onset of primary headache and decreased quality of life.

Triptans are used to treat acute migraine and cluster headaches.

Treatment of comorbidities may help patients overcome resistance or refractoriness to migraine therapies.

Researchers evaluated the safety, feasibility, and effectiveness of intranasal fentanyl in an adult population.

Navigating Cannabis use requires more than just an understanding of the endocannabinoid system.

Madison Irwin, PharmD, BCPS, discusses her career pharmacy and how she thinks high rates of chronic pain will impact the field in the coming years.

The calcitonin gene-related peptide monoclonal antibody significantly reduced the number of monthly migraine days.

No medications were associated with improved quality of life or reduced headache duration.

ATX101 from Allay Therapeutics is designed for use following total knee arthroplasty in adults and has shown positive results in multiple studies.

Pain, fatigue, and sleep disturbances are common symptoms with rheumatic diseases.

AMA released its 2024 Overdose Epidemic Report and presented key findings from the past year.

Most patients with reduced opioid prescriptions during cannabis use had chronic musculoskeletal pain.

Catch up on important nonopioid pain management news from November 2024.

A number of new, nonopioid osteoarthritis treatment options are either available for patients or in the development pipeline.